AX 024

Drug Profile

AX 024

Alternative Names: AX-024; AX-024.HCl

Latest Information Update: 22 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Artax Biopharma
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Nck protein modulators; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Asthma; Multiple sclerosis

Most Recent Events

  • 01 Jan 2016 Artax Biopharma completes a phase I trial in Healthy volunteers in United Kingdom (NCT02546635)
  • 22 Sep 2015 Artax Biopharma plans a phase I and II trial for Autoimmune diseases in United Kingdom
  • 01 Aug 2015 Artax Biopharma initiates enrolment in a phase I trial in Healthy volunteers in United Kingdom (NCT02546635)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top